Janux Therapeutics CEO David Campbell sells $300,004 in inventory

Janux Therapeutics, Inc. (NASDAQ:JANX), a $2.69 billion market cap biotech firm, noticed its President and CEO David Alan Campbell lately promote 5,000 shares of the corporate’s frequent inventory. The transaction, which happened on January 7, 2025, was performed below a pre-arranged Rule 10b5-1 buying and selling plan adopted by Campbell on June 21, 2024. The inventory has proven exceptional efficiency, delivering a 364% return over the previous 12 months.

The shares had been offered at a weighted common value of $60.0008, with the costs starting from $60.00 to $60.02. This sale amounted to a complete worth of $300,004. Following this transaction, Campbell retains possession of 293,054 shares in Janux Therapeutics.

The sale was executed by James Pennington, serving as Legal professional-in-Truth for Campbell, as indicated within the SEC submitting.

In different latest information, Janux Therapeutics has been the main focus of a number of analyst updates following promising scientific outcomes. Clear Avenue initiated protection on Janux Therapeutics, assigning a Purchase score with a value goal of $80, whereas Scotiabank (TSX:BNS) elevated its value goal to $62.00 and Jones Buying and selling raised its goal to $105. Stifel has additionally elevated its value goal for Janux to $115.00, sustaining a Purchase score on the inventory. TD Cowen reiterated a Purchase score, highlighting the spectacular outcomes from Janux’s ‘007 candidate.

These changes adopted the discharge of encouraging scientific information from Janux’s Part 1 research for JANX007, a remedy for metastatic castration-resistant prostate most cancers (mCRPC). The remedy demonstrated excessive prostate-specific antigen response charges, with all sufferers handled displaying a discount of at the very least 50% from the baseline. The continuing Part Ia dose escalation research of ‘007 is continuing alongside the initiation of the Part Ib growth, which is able to embrace second and third-line remedy settings.

These latest developments recommend that ‘007 might grow to be the popular non-androgen remedy for mCRPC, with the potential to generate a number of billions in income. The corporate is predicted to supply additional updates on ‘007, in addition to on ‘008, in 2025. The analysts’ optimism is predicated on the candidate’s robust scientific efficiency and the potential of ‘007 to fulfill a big unmet medical want within the oncology market.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.